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Abstract 
Treatment of metastatic kidney cancer has changed dramatically in the past years with 
the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We 
report here two cases of patients who benefited, both on disease control and side 
effects, from the addition of bevacizumab to temsirolimus, after progression on the 
mTOR inhibitor alone. 
 
Introduction 
Treatment of metastatic kidney cancer has changed dramatically over the past years 
with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance 
occurs. We report here two cases of patients who benefited from the addition of 
bevacizumab to temsirolimus. 
Case 1 
A 48-year-old man presented with several episodes of loss of consciousness in 2005. The MRI 
showed 2 hypervascular brain lesions. The CT scan showed a small right kidney tumour. He underwent 
right partial nephrectomy. Pathological examination of the surgical specimen showed a pT3aNx grade II 
clear cell carcinoma. The brain metastases were treated with gamma-knife radiosurgery. 
In 2006, he developed lung metastases and mediastinal lymph nodes. In March 2007, the mediastinal 
lymph nodes increased and he was started on sunitinib (50 mg 4 weeks on treatment and 2 weeks off). 
He had a partial response. In April 2008, the mediastinal lymph nodes increased and he developed 
lymphangitic carcinomatosis and required oxygen. He was switched to temsirolimus (25 mg IV/week). 
The lesions were stable but the lymphangitic infiltration was extensive and the patient still experienced 
dyspnoea. Bevacizumab was added to temsirolimus in July 2008. He improved dramatically, his oxygen Case Rep Oncol 2011;4:531–533 
DOI: 10.1159/000334581 
Published online: 
November 11, 2011
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
532
consumption decreased. On the CT scan the mediastinal lymph nodes and the lymphangitic 
carcinomatosis lesions improved. However, he progressed again in March 2009 and died in April 2009. 
Case 2 
A 54-year-old man presented with hematuria revealing a left kidney tumour in January 2004. He 
underwent a left radical nephrectomy. The pathological examination showed a pT2 clear cell carcinoma, 
Furman grade II tumour. In March 2005, he progressed with liver and lung metastases and he was 
enrolled in the phase III study comparing interferon to sunitinib. He had slowly progressive disease on 
interferon and crossed over to sunitinib in March 2006. He had a partial response. In July 2008, the lung 
and liver lesions were stable but he developed peritoneal carcinomatosis with ascitis. He was started on 
temsirolimus: ascitis was less abundant, the other lesions were stable. However, he became anaemic 
requiring blood transfusions. There were probably several causes to his anaemia (a side effect of 
temsirolimus and the disease). In January 2009, the liver lesions increased and he was started on a 
combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (20 mg IV weekly). His 
general condition improved, the anaemia disappeared, the lesions were stable and the ascitis much less 
abundant. He felt that he had fewer side effects on the combination treatment than on temsirolimus 
alone. However, in July 2009, he progressed and died in August 2009. 
Discussion 
These two cases show the effect of adding bevacizumab to temsirolimus for patients 
who were progressing on the mTOR inhibitor. Treatment of metastatic kidney cancer has 
changed dramatically in the past years with the use of VEGF-targeted therapies and 
mTOR inhibitors. The VEGFR tyrosine kinase inhibitor, sunitinib, is usually used in the 
first-line setting. Another tyrosine kinase inhibitor or an mTOR inhibitor can be used in 
the second-line setting, after progression on initial treatment. Mechanisms of resistance 
are not fully understood. Resistance to VEGF pathway inhibition can be caused by 
upregulation of alternative pro-angiogenic factors (FGF, angiopoietin…), inadequate 
target inhibition or enhanced receptor signalling [1]. Increasing VEGF blockade by 
combining therapies could be an interesting option in that case. There are a few cases in 
the literature of patients who were progressing on sunitinib and who benefited from the 
adjunction of bevacizumab; however, the first data show that these combinations are very 
toxic [2]. 
mTOR is formed of two multiprotein complexes: mTORC1 and mTORC2. Rapamycin 
and current mTOR inhibitors inhibit mTORC1 and not mTORC2. Inhibition of 
mTORC1 leads to compensatory activation of PI3K and AKT. This could drive 
upregulation of mTORC2 and further activation of Akt and HIF2α. This could therefore 
lead to increase of expression of HIF2α target genes, such as VEGF. Combining VEGF-
blocking agents with mTOR inhibitors could contribute to reversing resistance when used 
in a sequential manner. However, results from the TORAVA phase II randomized trial 
show no improvement of non-progression rates with the upfront combination of 
bevacizumab and temsirolimus but increased toxicity leading to a high drop-out rate [3]. 
There is no data in the literature on why patients should feel fewer side effects when 
adding bevacizumab to temsirolimus. However, some reports already mention the 
development of polyglobulia with anti-angiogenesis agent. This effect may correct a pre-
existing anaemia [4–6]. Case Rep Oncol 2011;4:531–533 
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